Common use of Health Outcomes and Economic Studies Clause in Contracts

Health Outcomes and Economic Studies. Studies reasonably anticipated to show the outcome and economic benefit of using Galectin-3, for example, like the HUMANA study on the role of Galectin-3 measurements at admission in the active discharge of HF patients. Other studies or efforts for the marketing portion of the Product Fee. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Exhibit 7.1

Health Outcomes and Economic Studies. Studies reasonably anticipated to show the outcome and economic benefit of using Galectin-3, for example, like the HUMANA study on the role of Galectin-3 measurements at admission in the active discharge of HF patients. Other studies or efforts for the marketing portion of the Product Fee. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Exhibit 7.1.

Health Outcomes and Economic Studies. Studies reasonably anticipated to show the outcome and economic benefit of using Galectin-3Galectin-3 , for example, like the HUMANA study on the role of Galectin-3 measurements at admission in the active discharge of HF patients. Other studies or efforts for the marketing portion of the Product Fee. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. Exhibit 7.1